Figure 1.
Study design (NCT02419612). DAPA, dapagliflozin; GLIM, glimepiride; IR, instant release; MET, metformin; SAXA, saxagliptin; XR, extended release
Study design (NCT02419612). DAPA, dapagliflozin; GLIM, glimepiride; IR, instant release; MET, metformin; SAXA, saxagliptin; XR, extended release